These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 7877990)

  • 1. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression.
    Dai Y; Schwarz EM; Gu D; Zhang WW; Sarvetnick N; Verma IM
    Proc Natl Acad Sci U S A; 1995 Feb; 92(5):1401-5. PubMed ID: 7877990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host.
    Poller W; Schneider-Rasp S; Liebert U; Merklein F; Thalheimer P; Haack A; Schwaab R; Schmitt C; Brackmann HH
    Gene Ther; 1996 Jun; 3(6):521-30. PubMed ID: 8789802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses.
    Ilan Y; Sauter B; Chowdhury NR; Reddy BV; Thummala NR; Droguett G; Davidson A; Ott M; Horwitz MS; Chowdhury JR
    Hepatology; 1998 May; 27(5):1368-76. PubMed ID: 9581693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression.
    Fang B; Eisensmith RC; Wang H; Kay MA; Cross RE; Landen CN; Gordon G; Bellinger DA; Read MS; Hu PC
    Hum Gene Ther; 1995 Aug; 6(8):1039-44. PubMed ID: 7578416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors.
    Ilan Y; Prakash R; Davidson A; Jona ; Droguett G; Horwitz MS; Chowdhury NR; Chowdhury JR
    J Clin Invest; 1997 Mar; 99(5):1098-106. PubMed ID: 9062369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscle as a target for supplementary factor IX gene transfer.
    Hoffman BE; Dobrzynski E; Wang L; Hirao L; Mingozzi F; Cao O; Herzog RW
    Hum Gene Ther; 2007 Jul; 18(7):603-13. PubMed ID: 17594244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice.
    Fields PA; Armstrong E; Hagstrom JN; Arruda VR; Murphy ML; Farrell JP; High KA; Herzog RW
    Gene Ther; 2001 Mar; 8(5):354-61. PubMed ID: 11313811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful expression of human factor IX following repeat administration of adenoviral vector in mice.
    Walter J; You Q; Hagstrom JN; Sands M; High KA
    Proc Natl Acad Sci U S A; 1996 Apr; 93(7):3056-61. PubMed ID: 8610167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.
    Fields PA; Kowalczyk DW; Arruda VR; Armstrong E; McCleland ML; Hagstrom JN; Pasi KJ; Ertl HC; Herzog RW; High KA
    Mol Ther; 2000 Mar; 1(3):225-35. PubMed ID: 10933938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells.
    Dobrzynski E; Fitzgerald JC; Cao O; Mingozzi F; Wang L; Herzog RW
    Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4592-7. PubMed ID: 16537361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.
    Kay MA; Landen CN; Rothenberg SR; Taylor LA; Leland F; Wiehle S; Fang B; Bellinger D; Finegold M; Thompson AR
    Proc Natl Acad Sci U S A; 1994 Mar; 91(6):2353-7. PubMed ID: 8134398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice.
    Zhang TP; Jin DY; Wardrop RM; Gui T; Maile R; Frelinger JA; Stafford DW; Monahan PE
    Gene Ther; 2007 Mar; 14(5):429-40. PubMed ID: 17066096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX.
    Ge Y; Powell S; Van Roey M; McArthur JG
    Blood; 2001 Jun; 97(12):3733-7. PubMed ID: 11389010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
    Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG
    Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice.
    Xu L; Mei M; Haskins ME; Nichols TC; O'donnell P; Cullen K; Dillow A; Bellinger D; Ponder KP
    Thromb Res; 2007; 120(2):269-80. PubMed ID: 17095052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.
    Herzog RW; Fields PA; Arruda VR; Brubaker JO; Armstrong E; McClintock D; Bellinger DA; Couto LB; Nichols TC; High KA
    Hum Gene Ther; 2002 Jul; 13(11):1281-91. PubMed ID: 12162811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses.
    Yang Y; Li Q; Ertl HC; Wilson JM
    J Virol; 1995 Apr; 69(4):2004-15. PubMed ID: 7884845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent expression of hF.IX After tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice.
    Sabatino DE; Mackenzie TC; Peranteau W; Edmonson S; Campagnoli C; Liu YL; Flake AW; High KA
    Mol Ther; 2007 Sep; 15(9):1677-85. PubMed ID: 17565352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of Hantaan virus-specific immune responses in C57BL/6 mice by immunization with a modified recombinant adenovirus containing the chimeric gene, GcS0.7.
    Li K; Li PY; Wu XA; Zhang L; Liu ZY; Yu L; Zhang L; Cheng LF; Bai WT; Zhang FL; Xu ZK
    Int J Mol Med; 2013 Sep; 32(3):709-16. PubMed ID: 23783439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.